MedTrace Logo

A Radiopharmacokinetic and Radiodosimetric Phase I Imaging Study of 18F-FAZA

NCT00756691 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2017-11-14

No results posted yet for this study

Summary

Hypoxia (little of no oxygen) is considered to be an important characteristic of a patient's tumour that may help predict patient outcomes and/or help inform patient management decisions. 18F-FAZA Positron Emission Tomography (PET) can detect hypoxic tumours because 18F-FAZA accumulates in hypoxic tissues. This study is being done to learn more about the processes by which 18F-FAZA is absorbed, distributed, metabolized (built-up and broken down) and eliminated by the body.

Conditions

  • Hypoxic Tumours

Interventions

OTHER

18F-FAZA

Radioactive dose of 110-600 MBq per injection. A single pre-treatment injection of 18F-FAZA will be permitted per patient

Sponsors & Collaborators

  • AHS Cancer Control Alberta

    lead OTHER

Principal Investigators

  • Alexander McEwan, MB, FRCPC · Professor, Department of Oncology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00756691 on ClinicalTrials.gov